Breast cancer in elderly patients: a clinicopathological review of a Nigerian database

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in patients with HER2 + mBC

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer

Opinion: Premature regulatory approval by the FDA

Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC

HER2DX confirms the ability of the test to predict long-term survival and response to anti-HER2 therapy in BC

Treatment decision guided by CTC count may improve long-term outcomes for mBC

Access to Oncology Medicines Coalition - The Medicines Patent Pool

Intraoperative ultrasound is accurate for guiding breast conservative surgery in non-palpable ductal breast carcinoma

Addressing women’s cancers: an economic evaluation of breast and cervical cancer interventions in Kenya

Long-term breast cancer risk after benign breast disease in population-based screening